To investigate the mechanisms of anaphylactoid reactions to protamine, we have examined the in vitro effects of increasing concentrations of protamine (10 it induced histamine release from human heart (mean 6.5 (SEM 1.5) %), skin (17.7 (4.1) %) and to a lesser extent from synovial mast cells, but not from lung mast cells. Protamine also caused the release of tryptase from heart mast cells (12.8 (3.2) g/10 7 cells), but did not induce de novo synthesis of LTC 4 and PGD 2 from lung and skin mast cells. In these experiments cross-linking of IgE by anti-IgE caused release of LTC 4 or PGD 2 from human basophils or mast cells. These results demonstrate that protamine acted as an incomplete secretagogue, causing the release of preformed mediators from human basophils and mast cells. (Br.
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To investigate the mechanisms of anaphylactoid reactions to protamine, we have examined the in vitro effects of increasing concentrations of protamine (10 96 
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) on the release of preformed (histamine and tryptase) and de novo synthesized (peptide leukotriene C 4 (LTC 4 ) or prostaglandin D 2 (PGD 2 )) mediators from human basophils and mast cells isolated from lung parenchyma, heart, skin and synovial tissues. it induced histamine release from human heart (mean 6.5 (SEM 1.5) %), skin (17.7 (4.1) %) and to a lesser extent from synovial mast cells, but not from lung mast cells. Protamine also caused the release of tryptase from heart mast cells (12.8 (3. 2) g/10 7 cells), but did not induce de novo synthesis of LTC 4 and PGD 2 from lung and skin mast cells. In these experiments cross-linking of IgE by anti-IgE caused release of LTC 4 or PGD 2 from human basophils or mast cells. These results demonstrate that protamine acted as an incomplete secretagogue, causing the release of preformed mediators from human basophils and mast cells. (Br. J. Anaesth. 1997; 78: 724-730).
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Protamine sulphate is a basic protein extracted from fish sperm heads. 1 The use of i.v. protamine to reverse heparin anticoagulation has increased in the past decade with the advent of cardiopulmonary bypass technology, cardiac catheterization, haemodialysis and leukapheresis. [2] [3] [4] [5] [6] However, protamine may be a major cause of morbidity and mortality in these procedures. 2 4 7-10 During the past decade, reports of adverse reactions associated with i.v. protamine (rash, urticaria, bronchospasm, hypotension and increased pulmonary artery pressure) have also increased. [2] [3] [4] [5] [6] The mechanism(s) by which protamine produces adverse reactions is still not completely understood. It has been suggested that they are caused by complement activation, 5 11 12 inhibition of serum carboxypeptidase, 13 thromboxane production 14 15 and anti-protamine IgE antibody via type I immediate hypersensitivity reactions. 2 6 It has also been suggested that protamine induces or potentiates histamine release from human basophils and mast cells. [16] [17] [18] Techniques are now available to isolate large numbers of mast cells from human lung parenchyma, 19 heart, 20 skin 21 and synovial tissues.
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These techniques have led to the demonstration that human basophils and mast cells isolated from different anatomical sites vary markedly in their morphological, biochemical and functional responses. [19] [20] [21] [22] [23] [24] [25] These cells differ with respect to the releasing activity of various stimuli and release of different preformed (histamine and tryptase) and de novo synthesized mediators (peptide leukotriene C 4 (LTC 4 ) and prostaglandin D 2 (PGE 2 )). 26 Preliminary evidence suggests that human basophils and mast cells may also vary in their histamine releasing capacity when challenged with general anaesthetics. For example, thiopentone activates skin mast cells 24 but not human basophils. It should be emphasized that previous studies have focused on the in vitro histamine releasing capacity of protamine [16] [17] [18] but have not evaluated its possible effects on de novo synthesis of chemical mediators.
To investigate the mechanisms of anaphylactoid reactions to protamine, we have tested in vitro to see if protamine induces the release of preformed and de novo synthesized mediators from human basophils and mast cells isolated from human heart, lung parenchyma, skin and synovial tissues.
Materials and methods

REAGENTS
The following were purchased: 60% HClO 4 26 The procedures for isolation of peripheral blood basophils and in vitro mediator release have been described in detail elsewhere. 29 The cell-free supernatant was assayed for histamine with an automated fluorometric technique. 29 Net percentage release was calculated by subtracting histamine released spontaneously from unstimulated samples (mean 3.6 (SEM 0.9) %) from total histamine released from cell samples lysed with 2% perchloric acid. 29 The difference between replicate histamine measurements was less than 10%.
ISOLATION AND PARTIAL PURIFICATION OF HUMAN
HEART MAST CELLS (HHMC) The heart tissue used in this study was obtained from patients (36-65 yr) undergoing heart transplantation at the Deutsches Herzzentrum, Berlin, mostly for cardiomyopathy. The explanted heart was immersed immediately in cold (4ЊC) cardioplegic solution, shipped to Naples by air (4ЊC) and processed within 5-18 h of removal. Fat tissue, large vessels and pericardium were removed from the heart (100-400 g). The tissue, was minced finely into 2-5-mm fragments, suspended in P buffer (10 ml/g of wet tissue) and washed three times by centrifugation (the first time 150 g, 4ЊC, 8 min and twice at 150 g, 22ЊC, 8 min). The heart fragments were filtered through a 150-m pore Nytex cloth (Tetko, Inc., Elmsford, NY, USA) and incubated for 15 min at 37ЊC under constant stirring in P buffer containing 10 mg collagenase/g of wet tissue. 20 28 Three additional cycles of enzymatic digestion were performed, with a new preparation of collagenase each time. After the last enzymatic digestion, the cell suspension was centrifuged (150 g, 22ЊC, 8 min) and filtered first through a 150-m pore Nytex cloth and then through a 60-m pore Nytex cloth to remove large particles and large cells (mostly myocytes). Lastly, cells were washed twice in PGMD (P 25 mmol litre ; pH 7.37) by centrifugation at 150 g, 22ЊC for 8 min. Cell pellets were resuspended in 250 ml of P buffer containing 2% BSA and centrifuged (25 g, 22ЊC, 2 min) to remove sedimented myocytes. 18 Myocytes (9100 m long) were pelleted and discarded; supernatants containing endothelial cells, fibroblasts and mast cells were then collected and centrifuged (150 g, 22ЊC, 8 min). At this stage of purification, Alcian blue-positive cells amounted to :1% of the total cells. HHMC were partially purified by flotation through a discontinuous Percoll gradient prepared by mixing 9 parts Percoll and 1 part 10 P solution. This mixture was then diluted with isotonic P to give Percoll concentrations of 40, 50, 60, 70, 80 and 90%. The cell suspension was overlaid on the Percoll gradient in 50-ml polypropylene tubes and the mixture centrifuged at 350 g, 22ЊC, for 20 min. The cells found at the interface between the 60-70% and 70-80% fractions were removed and washed twice with P. Mast cells in these populations ranged from 0.1 to 16%, with an average of 14.3 (2.4) %. The enzymatic dispersion of tissue yields ranged between 2 and 6 10 4 mast cells per gram of heart tissue.
PURIFICATION OF HUMAN LUNG MAST CELLS (HLMC)
Human lung tissue (20-80 g) was obtained from patients undergoing thoracotomy and lung resection, mostly for lung cancer. General anaesthesia was induced using the following drugs: droperidol with fentanyl and atropine (premedication); droperidol with fentanyl, thiopentone, suxamethonium and pancuronium (anaesthesia). Lung parenchymal mast cells were isolated as described previously. 19 This technique yielded between 3 and 8 10
5 mast cells/g of lung tissue, and purities ranged between 1% and 8%. 19 
PURIFICATION OF HUMAN SKIN MAST CELLS (HSMC)
Skin (15-65 g) was obtained from either mastectomies for breast cancer or elective cosmetic surgery procedures. General anaesthesia was induced using the following drugs: thiopentone, pancuronium, atropine, fentanyl, ethrane or fluorane. Tissue was placed immediately in Eagle's MEM at 4ЊC and used within 1 h. HSMC were isolated as described previously. 21 24 This technique yielded between 1 and 7 10 5 mast cells/g of wet tissue, and purities ranged between 1% and 4%.
PURIFICATION OF HUMAN SYNOVIAL MAST CELLS (HSYMC)
Synovial tissue (22-35 g ) used in this study was obtained from patients (27-66 yr) with osteoarthritis or rheumatoid arthritis, undergoing synovectomy at the Division of Orthopaedic Surgery. Extradural anaesthesia was induced with mepivacaine i.v. and atropine, fentanyl and benperidol were given systemically. Resected joint tissue was placed immediately in Eagle's MEM at 4ЊC and processed within 2 h of removal using a technique described recently. 22 Fat, cartilage and fibrous tissue were removed, and the tissue was minced finely with scissors into 2-5-mm fragments, suspended in P buffer (10 ml/g of wet tissue) and washed twice by centrifugation at 150 g for 8 min at 4ЊC and then at 22ЊC. The minced synovium was incubated for 45 min at 37 ЊC in a shaking water bath with chymopapain 1 mg ml 4 cells per tube) were resuspended in P2CG, and 0.3 ml of the cell suspension was placed in 12 75 mm polyethylene tubes and warmed to 37ЊC; 0.2 ml of each prewarmed releasing stimulus was added, and incubation was continued at 37ЊC for 30 min. 26 29 At the end of this step, the reaction was stopped by centrifugation at 1000 g 22ЊC for 2 min, and the cell-free supernatants were stored at 970ЊC for subsequent assay of histamine, tryptase, LTC 4 and PGD 2 content. The cell-free supernatants were assayed for histamine with an automated fluorometric technique. 29 To calculate histamine release as a percentage of total cellular histamine, "spontaneous" release from mast cells (2-12% of the total cellular histamine) was subtracted from both numerator and denominator. The total histamine content in mast cells was obtained by cell lysis with 8% HClO 4 . [24] [25] [26] All values are based on the means of duplicate or triplicate determinations. Replicates differed from each other by less than 10% in histamine content.
RIA OF TRYPTASE, LTC 4 AND PGD 2
Total tryptase content was assessed by lysis induced by incubating cells with 0.1% of Triton X-100. Tryptase was analysed by a solid-phase radioimmunoassay (Pharmacia Tryptase RIACT 50). 20 26 PGD 2 was analysed on 100-l fractions obtained from the supernatant fluids. The samples were stored at 970 ЊC. LTC 4 and PGD 2 were analysed by RIA within 18 h of the experiment to minimize degradation of the compounds. 23 
STATISTICAL ANALYSIS
Results are mean (SEM). Statistical analysis was performed by two-way non-parametric analysis of variance (Friedman's chi-square test). The extended Tukey test was used for multiple comparisons. The level of statistical significance was P:0.05.
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Results
In the first series of experiments we evaluated the effects of increasing concentrations (10 (table 1) . In one experiment, protamine released less then 5% of histamine content but in all other experiments release varied from 5% to 26%. The release caused by protamine reached a plateau between 10 95 and 3 10
95
, with less release above these concentrations. Anti-IgE, used as a positive control in these experiments, induced 28.9 (5.4) % of histamine release. There was no correlation between the maximum release caused by protamine and anti-IgE (r s :0.01; ns). Cell viability in the presence of protamine was always ജ95% as detected by trypan blue exclusion. 28 In the second series of experiments we compared the effect of protamine on histamine release from HHMC and HLMC. Protamine 10 ) of protamine on histamine release from mast cells from skin and synovial tissues. These concentrations of protamine induced histamine release from HSMC (table 2) and to a lesser extent from HSyMC (table 3) . The maximum release varied between 7% and 25% (HSMC) and 12% and 13% (HSyMC).
Tryptase is a neutral protease that is a selective marker for mast cells. 31 The secretory granules of all mature human mast cells contain large amounts (approximately 24.2 (4.3) g/10 6 HHMC of tryptase). 20 22 We investigated if activation of HHMC with protamine caused release of tryptase in addition to histamine. Tryptase was released in parallel with histamine from HHMC whereas protamine did not induce release of histamine and tryptase (:5%) from HLMC in three experiments ( fig. 2) . Different experimental models have shown that some of the adverse effects of protamine are caused by generation of eicosanoids. 32 33 We therefore compared production of the newly formed lipid mediators from human basophils and mast cells activated by protamine 10 .
In this group of experiments protamine induced concentration-dependent release of histamine from basophils, but did not stimulate de novo synthesis of LTC 4 by these cells (fig. 3 ). Anti-IgE stimulated release of large amounts of LTC 4 . Protamine also did not induce de novo synthesis of PGD 2 or LTC 4 from HHMC and HSMC, whereas anti-IgE stimulated the release of these eicosanoids (data not shown).
Discussion
Our results indicate that protamine is an incomplete secretagogue inducing only release of preformed mediators (histamine and tryptase) from human basophils and mast cells without stimulating de novo synthesis of eicosanoids. Protamine activated not only peripheral blood basophils, but also mast cells isolated from human heart, skin and synovial tissues, but not from lung parenchyma.
Intravascular administration of high concentrations of protamine is used increasingly to reverse heparin anticoagulation during cardiac catheterization, 4 cardiothoracic and vascular surgical procedures 34 35 and after dialysis 36 and leukapheresis. 37 I.v. protamine can cause acute reactions such as rash, urticaria, bronchospasm, hypotension, cardiovascular collapse, pulmonary hypertension and even death. 2 4 7-9 These adverse reactions are thought to be caused by multiple mechanisms, including anaphylactic [2] [3] [4] [5] [6] and anaphylactoid reactions. 11-14 16-18 Intravascular administration of protamine causes rapid and massive exposure of basophils to this agent. It is therefore likely that the release of histamine from peripheral blood basophils might at least partly explain some of the adverse effects of protamine in some patients. Intravascularly administered compounds rapidly expose circulating basophils and tissue mast cells to very high concentrations that tend to decline according to their pharmacokinetics. Thus we investigated the effects of a wide range of concentrations of protamine which must include concentrations reached during intravascular administration of the compound. The percentage of histamine release from basophils caused by protamine varied greatly from donor to donor, presumably because of the influence on basophil releasibility. 19 23 38 This may partly explain the wide variability of protamine-induced adverse effects in patients given this drug intravascularly. 6 At first sight, the bell shape of the dose-response curve of protamine on release of histamine from basophils might be surprising. However, other stimuli (anti-IgE, antigens, etc.) can produce a similar dose-response curve. 20 Although it has been demonstrated in different experimental models that the adverse reactions to protamine are to some extent caused by synthesis of eicosanoids and other lipid mediators, 32 33 protamine did not induce release of LTC 4 and PGD 2 from human basophils and mast cells in vitro. Possibly in vivo protamine induces the release of lipid mediators from other cells.
Radiocontrast media, which can cause anaphylactoid reactions, also act as incomplete secretagogues on human basophils and mast cells 26 and pretreatment with histamine H 1 and H 2 receptor antagonists reduces the incidence and severity of adverse reactions to these agents. 39 In the light of our results, it might be appropriate to investigate if these antagonists also reduce the incidence of anaphylactoid reactions to protamine.
Protamine caused a concentration-dependent release of tryptase from HHMC, HSMC and HSyMC. This neutral protease, present in the cytoplasmic granules of all human mast cells, 20 22 31 can activate complement leading to the formation of anaphylatoxins (C3a and C5a). 40 Complement activation and C3a formation can occur during in vivo administration of protamine [11] [12] [13] [14] and tryptase release from mast cells might therefore contribute, as an amplification factor, to the pathogenesis of the generalized reactions to protamine, through activation of the complement system. Tryptase has a longer half-life than histamine in plasma. 31 Therefore, it may be useful to measure plasma concentrations of tryptase in order to identify adverse reactions caused by protamine in humans.
Our results showed that protamine can induce release of vasoactive and proinflammatory mediators from HHMC in vitro. Coronary artery spasm, hypotension and shock can occur during intravascular administration of protamine. 8 9 Mast cells have been demonstrated clearly within human heart tissue, 20 28 around coronary vessels and in the shoulder region of atherosclerotic human coronary vessels. 41 During intravascular administration of protamine, cardiac mast cells are likely to be exposed to high concentrations and our findings suggest that in vivo they can thus be activated to release histamine, tryptase and possibly other mediators. Histamine exerts significant cardiovascular effects in humans 42 and vasoactive mediators released locally from coronary and cardiac mast cells might therefore contribute to the pathogenesis of severe adverse reactions to protamine.
Unlike HHMC and HSMC, HLMC were not activated by protamine in vitro. However, transient increases in pulmonary artery pressure are frequent when protamine is administered i.v. 7 14 It is therefore possible that the pulmonary reactions to protamine involve alternative mechanisms such as direct activation of basophils, tryptase-mediated formation of anaphylatoxins that in turn activate C5a receptors on HSMC 18 23 and HHMC, 20 or other unknown mechanisms. Our results were obtained with preparations of mast cells isolated from different tissues of patients receiving several drugs before and during surgical procedures. Consequently, we cannot exclude the possibility that some of the heterogeneous effects of protamine on the release of mediators from mast cells isolated from different tissues might be influenced by the in vivo treatment of the cell donors.
In conclusion, these findings suggest that protamine selectively activated different types of human mast cells and basophils, acting as an incomplete secretagogue. These results are of interest for several reasons. They contribute to a better understanding of the pathogenesis of immediate generalized reactions caused by rapid injection of protamine and they also suggest that anti-H 1 and anti-H 2 blockers might be useful in attenuating anaphylactoid reactions to this substance. Finally, they indicate that measurements of plasma tryptase might be useful to identify adverse reactions.
